Arbutus Biopharma (ABUS) EBT (2013 - 2026)

Arbutus Biopharma (ABUS) has reported EBT for 14 consecutive years, with $169.7 million the latest figure, recorded in Q1 2026.

• Quarterly EBT rose 791.81% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.5 million (up 308.22% YoY) and the FY2025 annual result came in at -$215.5 million, down 208.18% from the prior year.
• EBT improved to $169.7 million in Q1 2026 per ABUS's latest filing, from -$5.0 million in the prior quarter.
• Over the last five years, EBT for ABUS reached as high as $169.7 million in Q1 2026 and fell as low as -$24.5 million in Q1 2025.
• A 5-year average of -$4.3 million and a median of -$17.1 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT tumbled 44.32% — and 2026, when it surged 791.81%.
• Year by year, EBT stood at -$21.9 million in 2022, then gained by 11.95% to -$19.3 million in 2023, then jumped by 35.28% to -$12.5 million in 2024, then surged by 60.25% to -$5.0 million in 2025, then surged by 3515.86% to $169.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $169.7 million, -$5.0 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.